文献速递间质性肺疾病

SRRM2 新发变异与婴儿神经内分泌细胞增生症及持续性婴儿呼吸急促相关

D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy.
PubMed 文献 · Eur Respir J · 2026-02-05

本研究对 71 例临床表型明确的 NEHI/PTI 患儿行三代家系全基因组测序(n=21)和全外显子组测序(n=50),发现 4 例携带 SRRM2 新发功能缺失变异,且均伴轻度神经发育迟缓,提示 SRRM2 相关疾病表型应扩展至 NEHI/PTI。

要点

  • NEHI/PTI 患儿中 SRRM2 功能缺失变异检出率为 5.6%(95% CI 1.6–13.8%)。
  • 4 例携带 SRRM2 变异的 NEHI/PTI 患儿均合并轻度神经发育迟缓。
  • 建议 NEHI/PTI 患儿接受儿科神经科评估,并将 SRRM2 测序纳入常规检查。

核心结论

  • SRRM2 相关疾病是 NEHI/PTI 的单基因病因,其表型谱应扩展至 NEHI/PTI。
  • NEHI/PTI 患儿应接受儿科神经科评估,SRRM2 测序应纳入每例 NEHI/PTI 的检查流程。

研究设计与样本

  • 对 71 例临床表型明确的 NEHI/PTI 患儿行三代家系全基因组测序(n=21)以识别候选基因。
  • 随后对剩余 NEHI/PTI 患儿(n=50)行全外显子组测序筛查候选基因。

主要发现

  • 在 71 例具有典型肺部表现的 NEHI/PTI 患儿中,4 例检出 SRRM2 新发功能缺失变异。
  • 4 例携带 SRRM2 变异的 NEHI/PTI 患儿均合并轻度神经发育迟缓。
  • SRRM2 参与 mRNA 剪接,其功能缺失变异近期已在神经发育迟缓患者中报道。
  • 本队列 SRRM2 功能缺失变异检出率为 5.6%(95% CI 1.6–13.8%),比无肺病的神经发育迟缓患者中报道的频率高 20–100 倍。

临床怎么用

  • 对 NEHI/PTI 患儿应进行儿科神经科评估,关注神经发育迟缓。
  • 每例 NEHI/PTI 患儿的检查流程中应纳入 SRRM2 测序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuroendocrine cell hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is a major cause of childhood interstitial lung disease. This rare lung disease is responsible for respiratory insufficiency in the first years of life. Non-pulmonary symptoms have also been reported, including failure to thrive and developmental delay. The pathophysiology of NEHI/PTI remains unclear. To identify candidate genes of NEHI/PTI, we performed whole-genome sequencing (WGS) and whole-exome sequencing (WES) in a large cohort of deeply phenotyped patients. METHODS: Trio WGS was performed (n=21) to identify a candidate gene. Following identification of a candidate gene, WES was performed to screen this gene in the remaining NEHI/PTI patients (n=50). RESULTS: Four de novo loss-of-function (LoF) variants of SRRM2 were identified in four out of 71 NEHI/PTI patients with typical pulmonary presentation. Serine/arginine repetitive matrix protein 2 (SRRM2) is involved in mRNA splicing, and SRRM2 LoF variants have recently been reported in patients with neurodevelopmental delay (NDD). All four NEHI/PTI patients also had mild NDD. The prevalence of SRRM2 LoF variants in our cohort (5.6%, 95% CI 1.6-13.8%) is 20-100 times higher than reported in patients with NDD without lung disease, therefore the phenotypic spectrum of SRRM2-associated disease should be extended to NEHI/PTI. CONCLUSION: This study identifies SRRM2-related disorder as a monogenic cause of NEHI/PTI. These results suggest that NEHI/PTI patients should be evaluated by a paediatric neurologist and that SRRM2 sequencing should be included in every NEHI/PTI workup.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Louvrier C, Soreze Y, Mesinele J, et al. D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy. Eur Respir J. 2026. PMID: 40967764. doi:10.1183/13993003.00777-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。